Navigation Links
Conatus Pharmaceuticals Reports Positive Results of CTS-1027 in Multiple Preclinical Studies of Liver Disease
Date:11/5/2007

the integrity of the extracellular matrix. Excessive MMP activity has been demonstrated to occur in the liver in response to a variety of acute and chronic insults. This results in the loss of scaffolding that maintains the normal architecture of the liver and the recruitment and activation of inflammatory cells that perpetuate liver damage. In addition, important cytokines in the progression of liver damage, such as TGF-beta, stimulate the expression of MMPs from hepatic stellate cells, the main cell type involved in the pathology of fibrosis. MMPs are also well recognized to play an important and direct role in regulating inflammation. These dual activities of tissue remodeling and modulating inflammatory networks make MMPs an attractive target in the setting of acute and chronic liver disease.

Conatus Pharmaceuticals Inc. is a privately-held specialty pharmaceutical company engaged in the development of innovative human therapeutics to treat liver disease. Chronic liver disease affects millions of people worldwide and can be caused by many different conditions or "insults" to the liver including Hepatitis C and other viral infections, obesity, chronic alcohol abuse or autoimmune diseases. Conatus was founded by the executive management team of Idun Pharmaceuticals in July 2005 following the successful sale of Idun to Pfizer.

http://www.conatuspharma.com


'/>"/>
SOURCE Conatus Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/275q7t/inhaled_drug ) has announced the ... - November 19-20, 2015)" conference to their offering. ... industry case studies, regulatory updates, latest therapies and technology ... Steven Nichols , OINP Specialist Consultant and Mike ... participating include: - Aptar Pharma ...
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/hcb7bz/pharmaceutical ) has announced the ... - November 16-18, 2015)" conference to their offering. Regulatory ... including Columbia, Peru , Brazil , ... Uruguay , Paraguay , Venezuela ... Chile This seminar can be viewed ...
(Date:9/2/2015)... 2, 2015  Seeger Weiss LLP is reporting that ... commence October 13, 2015. Since the ... approval program, Zimmer NexGen knee implant surpassed FDA investigation ... companies provide evidence that the product is substantially similar ... gain permissions. In 2001, Zimmer began ...
Breaking Medicine Technology:Pharmaceutical Regulatory Affairs in Latin America Seminar - London, UK - November 16-18, 2015 2Seeger Weiss LLP Reports That Zimmer NexGen Knee MDL Bellwether Trial Date Set For October 13, 2015 2
... to Show That Extended,Thromboprophylaxis Reduces VTE Risk ... 44% , PARIS, July 8, 2007 /PRNewswire-FirstCall/ ... (EXtended CLinical,prophylaxis in Acutely Ill Medical patients) ... in acutely ill medical patients,with reduced mobility ...
... Positive Phase IIa Clinical,Trial Results, First clinical ... in AM-Pharma's Pipeline , BUNNIK, The Netherlands, ... novel therapeutics to treat,infectious and inflammatory diseases, ... Phase IIa Alkaline Phosphatase (AP) trial,for patients ...
Cached Medicine Technology:New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 2New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 3New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 4New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 5New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 6AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 2AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 3AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 4AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 5
(Date:9/2/2015)... ... , ... Leah Binder, MA, MGA, president and CEO of ... will offer the keynote address at the upcoming meeting of the ACO and ... Florida, at the Innisbrook Resort and Golf Club. For an agenda and registration, ...
(Date:9/2/2015)... ... September 03, 2015 , ... Each ... among America’s policymakers, public servants, activists, corporate executives, entrepreneurs, health care professionals, and ... year, that process led the magazine to tap the National League for Nursing’s ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... Symposium (WFS), cosponsored by the Military Officers Association of America (MOAA) and ... "Our Nation's Military: Caring For Our Own,” expert panelists will lead interactive ...
(Date:9/2/2015)... ... September 02, 2015 , ... Based in Beverly Hills, Luxury Line Auto ... luxury vehicles based on which of the latest and greatest vehicles their customers want ... in pursuit of this goal: a 2015 Rolls Royce Wraith rental in Los ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... (blinatumomab) – in the news recently following a decision by the Centers for ... – is likely to average approximately $71,000 or roughly 40% of its headline-grabbing ...
Breaking Medicine News(10 mins):Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 2Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 3Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 3Health News:MOAA and WWP host 2015 Warrior-Family Symposium Chairman of the Senate Committee on Veterans' Affairs and the Secretary of Veterans Affairs to Speak 2Health News:MOAA and WWP host 2015 Warrior-Family Symposium Chairman of the Senate Committee on Veterans' Affairs and the Secretary of Veterans Affairs to Speak 3Health News:Luxury Line Auto Rental Announces Addition of the Rolls Royce Wraith to their Luxury Fleet 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 4
... team looking for a cure for Duchenne Muscular Dystrophy, an ... findings// recently. ,The Stem cell Studies done by ... those who suffer from the disease. ,Duchenne muscular ... that results in muscle wasting which usually begins in ...
... of a communiqué from Britain about a novel type of ... Britain’s research farm, New Zealand authorities// have requested exact details ... has detected the disease, which is technically called ‘scrapie’ that ... disease. ,Barry O'Neill, the man at the helm ...
... directions for mandatory HIV/ AIDS testing before taking up ... asked the Maharashtra government to consider framing a policy ... PIL filed by an NGO, Maharashtra Law Graduate Association., ... that the National AIDS Prevention and Control Policy of ...
... adopted a new policy it hopes will inspire Australians to ... of life, AMA President, Dr Mukesh Haikerwal,// said today. ... country, with a robust culture of physical activity and the ... trend is blotting our image as a fit and healthy ...
... the NGO, Madras Round Table 1, in an altruistic ... diseases. The novel// partnership has been named ‘Save A ... one child per day’ they aim to give underprivileged ... SACH aims to assist early diagnosis and availability of ...
... may have COPD (Chronic Obstructive Pulmonary Disease), a serious ... general term used for a number of respiratory conditions, ... be the main cause. Early symptoms of COPD include ... during exercise or exertion. ,The Global Initiative ...
Cached Medicine News:Health News:Advance Australia Active – AM 2
Store microscope slides with ease, speed, efficiency....
... drawers for just about everything imaginable that might ... Each box is designed for long term storage ... of wood over metal systems is overlooked, while ... subtle kind of desiccator and insulator, providing an ...
A prepared Microscope Slide Cataloging and Storage System....
... resistant, plastic covered corrugated boxes interlock ... up to 500 lbs of overhead ... accommodates 2000 slides or 500 tissue ... requirements. Come unassembled boxes require minimal ...
Medicine Products: